The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year as well.
The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year as well.
SMART-on-FHIR is the inflection point for driving the shift to value-based care. The reason: It offers another pathway to integration in which user experiences, not just discrete data, are shared across systems, enabling lightning quick implementation.
The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We’re seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.
Technology has the potential to transform healthcare, by reducing the need for HCPs to perform repetitive, tedious administrative tasks such as documentation for regulatory and billing purposes.
The venture capital firm conducted a 12-month exhaustive search and found no dedicated venture fund for telehealth, Sid Jawahar, its founder and managing partner said. Swiftarc Telehealth will focus initially on obesity care, mental and behavioral health, and pediatrics.
Georgia lawmakers will consider a bill that could force the state’s Medicaid managed-care insurers to repay millions of dollars if their spending on medical care doesn’t reach a certain threshold.
TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within Foresite Labs and it now has $40 million to finance its research into this new realm of biology.
The current landscape heading into 2022 will keep pharmacy benefits under the microscope. Plan sponsors will evaluate their PBM’s pricing model to determine if their contract will deliver predictable costs, more opportunities for increased savings and improved care for their members.
Palliative care must be the standard of care for all who have been diagnosed with progressive, advanced, and terminal illnesses. Never should we hear the phrase, “I’m sorry, there’s nothing more I can do,” when physicians encounter the failure of a curative course of therapy.
Andrew Bott, Director of Talent Acquisition in EMEA & APAC countries at Medidata, shared his insights on hiring trends in this sector, in response to emailed questions.
Aequitas Partners Managing Director Tim Gordon shared what he’s seeing in the job market.
Employers can now submit open positions to the Jobs section on the MedCity News website.
Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.
Betty Chow, a Los Angeles resident, had a cervical disc replaced in August 2020 at […]
Six years in, the subtext of the scheduled reimbursements increase for 2022 is that CCM has proven to be an essential part of the care continuum, particularly in the wake of the Covid-19 pandemic, and has real value for patients, providers, and payers.
As virtual specialty care options continue to expand and access remains limited to dermatologists, Smart Health Innovation Lab announced this week that the platform, which allows people to do a full-body skin screening using a smartphone app, has joined the healthcare technology accelerator.
Mantra Health, which provides digital mental health tools for university students, raised $22M in a Series A funding round to offer its evidence-based teletherapy and psychiatric services to patients with long term mental health issues.
Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t reflective of the true value of the therapy the company is hoping to commercialize.
Gilead Sciences did not disclose details about the safety concern that led to an FDA partial clinical hold on five studies evaluating its cancer drug, magrolimab. But this experimental cancer immunotherapy introduces a safety risk that’s a known problem for all drugs in this class.
The Texas Medical Association (TMA) filed a brief on Monday to further oppose the ruling on the No Suprises Act that currently allows aribtrators to use the average in-network rate to determine out-of-network cost.
Sierra Oncology myelofibrosis drug momelotinib achieved the main and secondary goals of a pivotal test and the biotech now plans to seek FDA approval. Sierra acquired momelotinib from Gilead Sciences after that company stopped work on the drug due to mixed results in Phase 3 testing.
Basic organic chemicals used for the preparation of new medications cost over 54.8% more than they did 12 months ago. Further, with schools and daycare facilities either going fully remote and/or closed, many parents and caregivers had to stay at home, eliminating their availability for study participation.
Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.
By building greater understanding of context and flexibility into alternative payment models and enabling providers to make data-driven choices, we can begin to address inequities burdening VBC and help ensure APMs remain viable and enticing for healthcare providers.
Physicians may soon have a solution that could be ideal for preventing surgical site infections with a combined multi-layered system that provides the surgical site with controlled and continuous delivery of antibiotics.
It turns out that the laws governing traditional Medicare don’t provide for coverage of self-administered diagnostic tests. Medicare patients are left to seek free tests other ways, including through the administration’s new website, covidtests.gov, and at community centers.
Truepill’s COVID-19 test coverage platform will give clients a behind-the-scenes partner who can assist with everything from checking member eligibility for coverage to processing test orders and delivering tests to members’ homes.
Merck is still at the front of the pack of companies developing new medicines to treat chronic cough, but the company was dealt a setback as the FDA turned down the pharma giant’s application and asked for additional efficacy data. No safety issues were raised, according to Merck.
RecoveryOne will now offer their virtual physical therapy app for musculoskeletal (MSK) injuries as an in-network benefit to some Cigna Medicare Advantage Customers.
Although telehealth offers many benefits for patients, it introduces operational complexities for providers and creates legitimate concerns about fraud, waste and abuse for payers.
AI can process hundreds of thousands of products or contracts in one business day or less—an achievement that would take years if it was a manual task.
The FDA has rejected Pfizer’s somatrogon, a long-acting form of human growth hormone designed for once-weekly dosing. The setback delays Pfizer and partner Opko Health from competing against a newly approved human growth hormone drug from Ascendis Health that is also designed for once-weekly dosing.
Use of the newly ineffective treatments produced by Regeneron Pharmaceuticals and Eli Lilly is highest in a dozen states. They include several Southern states with some of the nation’s lowest vaccination rates, but also California, which ranks in the nation’s top 20 for fully vaccinated residents.
In this new era of digitally-driven healthcare, nurse informaticists play a pivotal role in ensuring the long-term success of new technologies and the physicians, nurses, and staff who use them.
A new study from Mayo Clinic found the Limber Health digital exercise therapy app – virtual physical therapy – is effective for musculoskeletal care, and it is now reimbursable.
The FDA placed the partial hold on the study last November following a patient death suspected to be linked to a known complication of leukemia therapies. Kura Oncology said it has reached agreement with the FDA on a mitigation strategy for that complication.
The new infusion brings Wheel’s total funding to $216 million at a time when more companies understand the need to have an on-demand consumer/patient-facing telemedicine service that Wheel possesses but may not necessarily want to build it from the ground up.
Eleusis is developing a formulation of the psychedelic compound psilocybin that overcomes limitations of pill versions of the drug. Depression is Eleusis’s lead disease target but the biotech notes that its research has shown the potential to bring psychedelic drugs beyond psychiatry.
The New York City-based digital medicine company has been working with the health system for several years, starting in its gastroenterology department. It’s providing a unified messaging platform aimed at improving care coordination and patient engagement.
Despite the targeted approach of some cancer treatments, tumors can find ways to escape, leading patients to relapse. ImmPACT Bio will apply its Series B financing toward the development of cell therapies designed to prevent tumor escape.
A report that surveyed 500 healthcare providers found that medical providers have reached a breaking point in terms of stress and burnout and one area contributing to the stress is poor medication management.
Epilepsy is a small part of UCB’s neurology pipeline, but its proposed Zogenix acquisition would broaden the Belgium-based drugmaker’s ability to address that market. Zogenix’s Fintepla is approved in the U.S. and Europe for a rare type of epilepsy called Dravet syndrome, and is in development for other rare epilepsies.
ProKidney is going public in a SPAC merger that infuses the biotech with $825 million for Phase 3 tests and manufacturing of its autologous cell therapy for chronic kidney disease. More than slowing the decline in organ function, ProKidney says its cell therapy offers the potential to reverse injury caused by the condition.
Managing the healthcare workforce can be a challenge for providers, particularly in the current environment. There has never been a greater need for a holistic approach to workforce management. DXC Technology offers solutions to a wide range of increasing healthcare industry business needs.
The FDA rejected the new drug application for a Levo Therapeutics treatment for the rare metabolic disorder Prader-Willi syndrome. According to Levo, the agency said the data submitted were insufficient to support approval and the regulator wants the company to run another clinical trial.
A growing number of transition programs are focused on healthcare planning – helping formerly incarcerated individuals with enrollment in Medicaid, and supporting them to access covered programs to treat medical and physical health conditions.
Yuvo Health announced Tuesday that it has raised $7.3 million to support the company’s work with federally qualified health centers. The startup says the services it provides will help the centers unlock revenue streams via value-based care.
Over the last century, women’s health needs began to receive the attention they deserved from medical professionals. Men’s health, underserved in the digital space and stigmatized in public conversation, deserves a similar revolution.
Like the climbing route Tommy Caldwell pioneered on El Capitan in Yosemiteb, no template exists for transforming the digital health experience. This is new ground for the industry, and organizations need a structured approach.
Centers for Medicare & Medicaid Services only recently gave the green light for Medicare Advantage (MA) plans to provide a wider range of benefits that address social determinants of health. With that new charge, it’s time for health care payers to join the fight against loneliness.
Digital health company Verana Health has raised $150 million. The company said it will use the new capital to expand its technology, which is used by physicians and pharmaceutical companies.
The report, published by Microsoft, is based on interviews with more than 9,600 frontline workers from eight industries and eight countries. and proposes technology as a solution to help address issues and burnout impacting frontline workers.
Bausch + Lomb is returning to the public markets in an IPO expected to rank among the biggest in healthcare. Speaking at the annual J.P. Morgan HealthCare Conference, Bausch Health Companies CEO Joe Papa discussed the plans to spin off both the iconic eye products business as well as the skin products business, leaving three […]
When we look at wellness from a holistic view and identify goals to achieve and sustain a healthy lifestyle, individuals and their communities will reap the benefits. This, in turn, will positively impact the healthcare system by reducing costs and promoting wellness in society.
Check out new developments from Carrum Health, Health Mine, and more.
We are building upon the foundation of digital laparoscopy and adding machine vision, augmented intelligence, and deep learning capabilities.
The Artificial Intelligence Industry Innovation Coalition (AI3C) leverages the collective brainpower, experience and expertise of the Brookings Institution, Cleveland Clinic, Duke Health, Intermountain Healthcare, Microsoft, Novant Health, Plug and Play, Providence, UC San Diego and University of Virginia.
The FDA placed a clinical hold on Denali Therapeutics’ application to begin Phase 1 testing of an antibody drug for Alzheimer’s disease. The Denali drug uses the biotech’s proprietary technology to deliver therapeutic cargo across the protective blood-brain barrier.
Blue Cross Blue Shield of Massachusetts is leveraging data and value-based contracts to reduce disparities it has observed and publicly revealed within its own patient population, while also providing financial support to groups that help physicians address health equity.
Te justices blocked a key Biden administration Covid-19 initiative — putting a stop, for now, to a rule requiring businesses with more than 100 workers to either mandate that employees be vaccinated against covid or wear masks and undergo weekly testing. But said that a separate rule requiring Covid vaccines for an estimated 10 million […]
Providers, payers, and life sciences companies have a lot of room for growth using AI, and investors participating in JPM will continue to focus on companies that recognize this and act on it.
AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target with small molecule drugs. Depending on the progress of the research, Scorpion could receive up to $1.5 billion in option fees and milestone payments.
Digital health will alter HIPAA compliance – one of five predictions in this article about what the future portends in healthcare.
In the runup to MedCity INVEST in Chicago, we’re spotlighting the perspectives of investors and what motivates them to invest in startups. If you’re a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
BeyondSpring Pharmaceuticals’ corporate reorganization comes about six weeks after the FDA rejected the biotech’s drug for a complication experienced by cancer patients. The company still plans to develop the drug for that application and others, but it added that layoffs are needed to reduce expenses.
OSF HealthCare has made 26 direct investments to date in addition to investing in three healthcare-focused venture funds. The latest venture fund is the largest at $100 million, putting total assets for its investment program at $250 million.
Abbott wants to leap into the world of consumer wearables to track various health signals for better health for consumers and better growth of its business. Will it win hearts and minds?
Sanofi is the latest company to strike a deal for a Parkinson’s disease drug candidate that targets the protein alpha synuclein. The asset from ABL Bio is a bispecific antibody designed to penetrate the blood-brain barrier.
Boston Consulting Group published a new report that identifies five challenges facing healthcare in the upcoming 3 to 5 years as a result of the pandemic and digital shift.
A differentiated – and superior – member experience can drive tremendous value for payers. Here are three ways health insurers can make that happen.
The National Pancreas Foundation and Seqster are partnering to create a dynamic digital database for patients with pancreatic diseases that compiles patients’ data from genomic DNA test, EHR, and wearable/remote monitoring device to speed up research for pancreatic disease treatments and provide more cohesive treatment for patients.
The Center for Medicare and Medicaid Services proposes covering Biogen Alzheimer’s disease drug Aduhelm only for people enrolled in a clinical trial. In explaining this proposal, the agency cited the unclear benefit to patients as well as the documented safety risks associated with the drug, which can be best monitored within the context of a […]
Transcarent is the latest entrant in the world of healthcare unicorns announcing a $200 million Series C investment round led by Kinnevik and Human Capital. Other investors in the round included top health systems.
On a panel discussion about employer-sponsored health benefits, the CEO of Morgan Health outlined some priorities and new efforts to reign in healthcare costs for employees while also providing them convenience and choice.
A month after Freenome closed $300 million in financing, Roche has invested another $290 million in the diagnostics developer. The cash infusion comes as Freenome continues a pivotal test in colorectal cancer while it also readies for clinical trials in other types of cancer.
The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
The deadline to apply to the MedCity INVEST Pitch Perfect contest in Chicago, scheduled for March 28-30 at the Ritz Carlton, is January 31.
In a virtual panel discussion about public and population health at J.P. Morgan’s annual conference, the CEO of Aledade shared how the quest for efficiency in a world of harried physicians’ practices almost led Aledade to use a flawed ML algorithm to engage at-risk patients of those practices.
A leader in telemedicine, Teladoc’s stock is on a slide. But company leaders expect that investors will come around as the company continues to grow, gain customers and retain existing patients.
Bristol Myers Squibb is partnering with Century Therapeutics, placing a $150 million bet that the biotech’s technology for engineering stem cells can produce new off-the-shelf cell therapies for cancer. If the four potential programs covered under the pact reach the market, milestone payments could bring Century more than $3 billion.
Physicians Advocacy Institute, American Association of Neurological Surgeons, and Congress of Neurological Surgeons lead a coalition of physicians groups in filing an amicus curiae brief backing the American Medical Association and American Hospital Association’s lawsuit opposing the dispute regulation guidelines of the No Surprises Act that went into effect January 1.
Geoff Martha participated in the 40th annual J.P. Morgan Healthcare conference virtually explaining key decisions, accepting responsibility for a trifecta of bad news while also signaling that all will be well in the future at the Dublin-based medtech giant.
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that expand give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.
If you can achieve the right mix of high-tech, high-touch options, you’ve hit the sweet spot for improving equity and accessibility, patient engagement, health outcomes, loyalty, and profitability
Lower courts have split on whether the federal government has the authority to issue such rules and whether they can take effect while the cases are argued.
It’s the first week of the new year, and the life sciences sector continued the IPO momentum of 2021 as Wall Street welcomed three new biotech companies. Here’s a look at the IPOs of Amylyx Pharmaceuticals, CinCor, and Vigil Neuroscience, which raised a combined $482 million to support work on drugs addressing neurodegenerative and cardiovascular […]
Binah.ia has made its contactless, video-based blood pressure measurement technology commercially available to businesses.
When Californians go to the polls later this year, they will confront contentious healthcare choices. […]
The CEO of Surescripts believes we are living in an unpredictable world coupled with an explosion of innovation that aims to solve challenges like the cost of medications, administrative inefficiency and gaps in patient information.
In 2021 biotech had a median deal of $10 million and an average deal of $36.9 million, according to the report by PitchBook Data. Comparatively, medtech locked in an median of $3.9 million and $12.6 million average.
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
Child and adolescent mental health, palliative care and clinical AI are among opportunities that investors should consider closely this year an in the future.
Check out new developments from DNA Script, DermBiont, Healthmine, and more.
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
One reason clinicians struggle to find what they need in EHRs is because most legacy systems were not designed to provide a diagnostically holistic view for specific clinical conditions.
A Sanofi strategy shift is leading to the end of a gene-editing alliance with Sangamo Therapeutics. Though the partnership has produced encouraging early clinical data with a sickle cell therapy highly personalized to the patient, Sanofi now plans to focus on universal approaches to genomic medicines.
This is the time to embrace radical empathy, profound change, and bold ideas. While the pandemic may have put us all on an unexpected path, there is no turning back from here.
We may acknowledge just how essential the nomadic healthcare workforce has been in efforts to control the Covid-19 pandemic, but what’s often overlooked is how and where these workers are being housed.
Vera, a value-based primary care provider, will buy all the outstanding shares of Castlight, in a move that will merge the two companies.
The conversation about medication shouldn’t end when the prescription is written. Physicians need to be accessible to patients to talk about how the medication is working for them, how often they are using it as prescribed, and what barriers they have to using it.
Pfizer is paying BioNTech $225 million to kick off a new alliance aiming to develop a shingles vaccine based on the same messenger RNA technology that is the basis of the partners’ Covid-19 vaccine. It’s the third alliance between the two companies, but this time Pfizer brings something more to the table.
Oncolytic viruses have the power to make the tumor more visible to the immune system and mark the area of attack. It is this anti-tumor immune activation that has the potential to induce long-term responses in patients.
Regence is partnering with Strive Health to deliver comprehensive kidney care to 16,000 Regence Medicare Advantage and commercially insured plan members in several Western states.
Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken up by patients. No safety problems were reported, but the biotech said it now plans to focus its other gene therapy candidates for rare metabolic disorders.
To improve heart attack prevention, there is an urgent unmet need to modernize our approach from late-stage symptom-driven care to direct disease-based care, a care paradigm that addresses heart attack risk in all patients across the entire continuum of heart disease severity.
Health analytics firm Aetion has acquired Replica Analytics, a company that specializes in synthetic data. Aetion said Replica will enable it to analyze previously inaccessible data while maintaining privacy and integrity of the original source data.
There are resources medical institutions can draw on to relieve some of the burden from overworked, stressed-out physicians, nurses and staff – and many of them come in the form of technological advancements that may transform how we offer care in the years to come.
In order to benefit from the Virtual1Care trend, pharma and medtech companies must ensure that their digital health tools, wrapped around a drug or device, comply with evolving regulations.
“Most Q&As are happening on Twitter. If you’re not doing social listening you’re losing fresh insights into things like disease states.” That was just one of the observations in a new report on how pharma and other life science companies are working with healthcare providers and adapting to improve the patient experience.
The FDA has expanded emergency authorization of Covid-19 boosters to include children 12 to 15 vaccinated with the Pfizer and BioNTech messenger RNA shot. The decision is based on a study that found boosting reduced deaths by 90%, but that Israeli analysis only evaluated these shots in people 50 and older.
Ovid Therapeutics is acquiring global rights to AstraZeneca molecules that address a novel target to treat epilepsy. The AstraZeneca deal comes 10 months after Takeda Pharmaceutical paid $196 million up front to acquire Ovid’s rights to a Phase 3 ready molecule for two rare forms of epilepsy.
For many health researchers, when it comes to engaging with specific audiences, you don’t know what you don’t know. Don’t assume you understand your target audiences. Don’t use your language to engage with them. Connect with them. Learn from them.
Your company cannot thrive if you’re weighed down by brain fog and working with exhausted team members who have lost faith.
There will be more pilots and programs of value-based reimbursement contracts between payers and providers. The traditional fee-for-service model won’t disappear for years to come, but there will be thoughtful pilots of reimbursement programs that reward providers for quality of care and clinical outcomes.
After a busy year for digital health, four experts shared their predictions on which sectors will see the most M&A, and which companies are likely to get together in the future.
As in previous years, cancer products topped the list of new FDA-approved therapies in 2021. But the list of drug approvals is notable for other trends, including developments in rare diseases and regenerative medicine.
While hospitals are slow to comply with the price transparency rules, full compliance will eventually mean hospitals provide “machine readable files” with thousands of lines of pricing data.
In the post-pandemic world, care teams–from providers to insurers – must increase personalization and reduce complexity to empower consumers to engage more in their health and drive better care outcomes.
The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even though IPOs reached record levels this year that streak is not expected to continue in 2022.
As health systems play catch up with backlogged – and potentially life-saving – screenings, it’s important they prioritize people at higher risk, to ensure they have access to the preventive care they need.
The FDA has accepted Amylyx Pharmaceuticals’ submission for amyotrophic lateral sclerosis drug AMX0035 and it expects to issue a regulatory decision by late June. A lot will happen before then. Amylyx recently filed for an IPO and the company’s drug is slated for an advisory committee meeting ahead of an FDA decision.
As new information around vaccines and children continues to evolve and surface, maintaining a single point of entry for this information, that is updated in a timely fashion, can be incredibly helpful to caregivers.
Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing advantage. The Pardes pill is in Phase 1 testing, and the biotech joined the public markets this week after completing a SPAC merger that infuses the company with $274 million.
For healthcare providers, supply chain woes are a reminder of the havoc that results when a single element of a trusted delivery model breaks down.
With FDA approval for its atopic dermatitis drug Adbry, LEO Pharma will reach the U.S market ahead of an Eli Lilly atopic dermatitis drug that addresses the same target. LEO will also able to offer patients an alternative to the blockbuster Sanofi/Regeneron Pharmaceuticals drug Dupixent.
Given the rapidly evolving nature of patient expectation, it’s clear that healthcare providers must find ways to transform their services and experiences to deliver a truly omnichannel healthcare experience (HX) that unifies care across both in-person and digital touchpoints.
BridgeBio reported its drug acoramidis missed the main goal of a pivotal study in patients with transthyretin amyloidosis affecting the heart—the same type of patients helped by a currently approved blockbuster Pfizer drug. BridgeBio attributed the trial failure to a surprisingly strong placebo response, and it will continue the study, hoping for better outcomes on […]
For those patients discharged from a long-term care facility back into the community, provider teams must work to ensure continuity of care is preserved and that patients receive the same quality and level of care in their homes as they did while in an institutional setting
In addition to Buy Now Pay Later payment plans, digital communication tools like QR codes and text messages have found new relevance in healthcare as they have become normalized through changes made to consumer payment experiences.
Rather than continuing to pour scarce resources into additional salaries, bonuses, benefits, and recruiting, providers should consider investing in digital patient engagement tools that enable existing staff to work more efficiently and at the highest of their abilities.
The World Health Organization (WHO) is already prompting leaders to consider ethical responsibilities and dilemmas of integrating AI more heavily into care, posing questions around maintaining human autonomy, ensuring transparency, and establishing inclusiveness and equity.
Read about news from DermBiont, Janus Health, Embold Health, digital health draft guidance from the FDA, and more.
Merck antiviral drug molnupiravir received emergency authorization, joining Pfizer’s Paxlovid as the only authorized oral antiviral drugs for treating Covid-19. Though the Merck and Pfizer antivirals appear to work against the omicron variant, FDA officials stressed that these drugs are authorized only for certain patients and they are not a substitute for vaccination.
Utilizing all available data sources to optimize clinical trial design and plan as well as adopting novel trial formats, such as decentralized trials, telehealth and mobile health applications, can get us closer to that holy grail: conducting a fast, successful clinical trial – and even reduce cost.
While hospital-based initiatives to address maternal and infant health are important, it is clear that problems surface long before and after delivery.
By enhancing traditional in-person care with on-demand digital solutions, we can create a powerful new care model that maximizes clinical resources while meeting patients whenever and wherever they need support.
Novartis is acquiring gene therapy developer Gyroscope Therapeutics and its lead program, a potential treatment for the vision loss disorder geographic atrophy. It’s the latest in a series of M&A moves made by Novartis to build up its gene therapy pipeline.
A report breaks down the merits and disadvantages of different types of cloud vendors to help healthcare organizations advance their healthcare digital transformation goals.
Funding for digital health is blowing up, and the sky’s the limit for a healthcare world suddenly, and solidly, committed to tech innovations. Here’s what we can expect to see more of next year.
The FDA has halted tests of a Pfizer gene therapy for Duchenne muscular dystrophy. The clinical hold is one of several placed on gene therapy tests in the past year due to safety concerns.
What draws investors to healthcare startups? In this series in the runup to MedCity INVEST in Chicago, we’ll highlight these perspectives. If you’re a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
To help revenue cycle leaders shortcut reporting efforts and ultimately collect more dollars, the following are five questions they should ask about their account receivables worklists to identify opportunities for performance improvement.
Insurers that didn’t meet medical loss ratio requirements have paid out a total of $2 billion in rebates to nearly 10 million people, split between people who received their insurance through individual market plans and group plans.
The company would become part of GE’s ultrasound business, expanding its capabilities to include surgical visualization. GE plans to spin out its healthcare division into a publicly traded company in 2023.
In acquiring Amunix, Sanofi becomes the latest big pharmaceutical company to strike a deal to gain access to technology that improves the safety and efficacy of T cell engager cancer therapies. Sanofi agreed to pay $1 billion up front to buy preclinical Amunix.
The Covid-19 pandemic has brought a laser focus to the critical and immediate need for next-generation sequencing tools that can generate invaluable data for not only identifying emerging variants but for understanding the functional and epidemiological consequences of variant-specific mutations.
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene’s antibody drug.
What follows is guidance for healthcare workers, hospital administrators, journalists, nonprofit leaders, government officials, industry leaders, and others who want to invite engage a patient safety advocate to share their story at an event, or to collaborate on a research or awareness project.
The price of Biogen Alzheimer’s disease drug Aduhelm will be cut in half at the start of 2022, a move that comes as a Medicare recommendation on coverage is expected early next year. Meanwhile, Biogen is preparing corporate measures projected to save $500 million annually, cost-cutting made necessary in part due to slow market uptake […]
A conversation with Taha Kass-Hout reveals how machine learning can be leveraged to really harness data to improve outcomes and ultimately put people on a path to precision health.
The change in terminology from “compliance” to “adherence” is based on unfounded and untenable foundations. It conflates cause and effect, and a shift in language and mindsets can help reframe and better tackle the core problem: patient failure to take medications as prescribed.
Interoperability has risen to the forefront, empowering providers and payers with the information they need to implement value-based care models.
With the proliferation of IoT and connected OT devices in hospitals, asset management – the process of creating an inventory of the devices connected to a network – is increasingly difficult.
Myasthenia gravis patients now have a new FDA-approved biological treatment. Argenx drug Vyvgart provides a treatment alternative for patients who have the rare autoimmune disorder and also marks the first approved product in a new class of medicines.
Digital health companies have now raised more than $20 billion in 2021, more than any other year. While experts expect to see the dealmaking continue, they raised caution about the challenges of going public with high valuations.
Oracle is reportedly in talks to buy Cerner for $30 billion, according to the Wall Street Journal. If it closes, it would be the largest health tech deal this year.
Cultural resilience aims to institutionalize aspects of a business culture distinguished for how mental health is valued and understand the inextricable link between mental wellbeing and productivity.
The insurers referred to deals Gilead struck with Janssen, Bristol Myers Squibb to prevent the generic version of its retroviral medications from being used as part of combination treatments. They also allege the company struck a deal with Teva to delay the release of its generic drug.
Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but is currently in Phase 3 testing in another liver disease, primary biliary cholangitis. Meanwhile, Genfit is adding an early-stage drug candidate to its own pipeline via a separate transaction.
While the era of using digital health tools to manage MCI and perhaps prevent greater cognitive decline is just beginning, it is a promising new therapeutic direction for a very complex condition. The more these solutions are developed and studied, it seems clear, however, that the most effective technology will be the systems that individuals […]
We cannot simply accept that testing new drugs will continue to be a slow and expensive process. AI has the potential to disrupt the current approach to clinical trials — from patient recruitment to adherence monitoring and data collection – and it is time to seize these opportunities.
Check out new developments from Seven Bridges Genomics, Carrum Health, Healthmine, and more.
Nurses and health care workers across the country are finding strength in numbers and with […]
Three life science companies unveiled Series B rounds of funding Thursday, early Christmas gifts that top $219 million combined. Along with Verge Genomics, the other companies that raised new capital are Tasso and Brainomix.
Unless we’re careful, digital health will go down the same path as our legacy health systems as the rush to compete prompts consolidation that misaligns incentives.
Six months after Biogen was awarded regulatory approval for its Alzheimer’s disease drug Aduhelm, the company the company is laying out a timeline for the post-marketing study to confirm whether the drug works. The projected four-year study will enroll more than 1,300 patients and will include a placebo control arm.
Technology’s proliferation in the next year can make this system even more effective, helping patients and providers thrive in 2022.
Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics’ FateControl technology ensures that more of an ADC’s drug payload reaches the tumor, and CEO Alex Nichols is steering the startup out of stealth with $103 million and a lead program in lung […]
Bristol Myers Squibb has notched another FDA approval for its blockbuster immunology drug Orencia, this time for preventing acute graft versus host disease in bone marrow and stem cell transplant patients. The decision makes the BMS drug the first one approved for preventing this complication of transplant procedures.
This is what we have known for years: medical care alone does not equal better […]
The startup is looking to help launch health plans by handling some of the administrative components. It bills itself as a tech-forward third-party administrator, and can help manage claims and enrollment.
The company, which is building a cloud-based platform to help health systems pull health records together, recently closed a $150 million funding round.
It is time for Medicare to move past legacy data storage and look to the incorporation of healthcare data platforms that provide beneficiaries with direct, unified access to their data and a way for providers to get a complete picture of their patients.
A recent webinar hosted by MedCity News and sponsored by BioT shared insights on some of the ingredients to successful creation and execution of remote patient monitoring solutions supported by a cloud-based connected care platform with speakers from BioT and Abbott.
CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.
A panel of judges on the 8th Circuit Court of Appeals declined to reinstate a vaccine mandate for healthcare workers that was set to go into effect in January. A federal judge had blocked the mandate last month from the Centers for Medicare and Medicaid Services after 10 states filed suit.
Virtually all routine dialysis should be available within skilled nursing and long term care facilities. The technology for this type of care exists and training LTC staff on easy to operate, portable dialysis devices should be the norm.
Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and […]
A blended navigation model that includes a transformed pharmacy benefits offering is the industry’s best opportunity for overall cost reduction in an employer space that desperately needs it.
The American Medical Association, American Hospital Association and other provider groups are suing the Department of Health and Human Services over a small but important detail of how it is implementing surprise billing legislation. They argue that the arbitration process for unresolved disputes currently favors insurers.
A look at how healthcare organizations are collaborating with Microsoft to enhance patient engagement, accelerate healthcare innovation, improve clinical and operational insights, and more.
Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
According to Rock Health’s annual consumer adoption survey, telehealth users tend to be higher income, younger and live in urban areas. The survey also tracked people’s satisfaction with telehealth and what modalities people used most to access care.
Eli Lilly is building its cancer drug pipeline via a research alliance with Foghorn Therapeutic, a biotech whose technology discovers drugs addressing targets in a cellular system that regulate the way genes are turned on and off. In paying its new partner $380 million up front, Lilly is also placing yet another bet on targeted […]
ntegrated software, accessible genetic data, and advances in precision medicine can transform the lives of millions of patients–if the clinical trial and larger medical industry embrace these trends.
The FDA granted 510(k) clearance to two of Philips’ newest acute care patients monitors, the IntelliVue MX750 and MX850. A year ago, the company had gotten an emergency use authorization for its monitors.
The Cuthbert hospital in Georgia was one of 19 rural hospitals in the U.S. that closed in 2020. That’s the largest number of such facilities to shut down in a single year since 2005.
Cigna Ventures and Bright’s majority shareholder, New Enterprise Associates, are contributing to the financing. It comes as Bright faces higher-than-expected medical costs during the pandemic.
Read about new developments at Neuroflow, Healthmine, Breakout Ventures and more.
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of Color explained what they think needs to happen to make these tests accessible and affordable for more people.
FDA authorization of AstraZeneca drug Evusheld makes it the first antibody therapy for preventing infection before exposure to Covid-19, providing an option for immunocompromised patients who won’t mount a strong immune response to vaccination. The antibodies that comprise the AstraZeneca drug are engineered with technology that makes the therapy long lasting.
The company is working on a voice assistant to lighten clinicians’ documentation burdens by automating some of that work. It faces competition from large companies like Nuance, which was acquired by Microsoft earlier this year.
Existing claims and clinical workflow-based legacy technology investments, both on the payer and provider sides, simply are not equipped to efficiently administer value-based arrangements at scale.
At CB Insights’ Future of Health Conference, Ginger CEO Russell Glass talked about how the company merged with Headspace to form a $3 billion mental health company and how to scale up a mental health business.
PharmStars, an accelerator for companies developing digital solutions for pharmaceutical companies, has graduated its first class of startups. The theme for this initial group was “innovation in clinical trials.”
The company recently raised a $300 million funding round led by Softbank’s second vision fund. It’s one of several digital health startups looking to address access to mental healthcare.
Preliminary data suggest the BioNTech and Pfizer Covid-19 vaccine may have diminished protection against the omicron variant, but that levels of neutralizing antibodies can be restored with a third shot. Real-world data are needed to further assess the vaccine’s efficacy against the new variant and whether an omicron-specific version of the shot is needed.
We now know how important white matter is to our overall brain health and cognitive ability, as well as how declines in white matter structure are correlated with impairments in brain function.
Technology already exists in many forms that can reduce the impact of Covid-19 in marginalized communities, but it has largely been overlooked
The Cambrian explosion refers to an intense burst of growth in life forms on earth during a relatively short time in the Cambrian period, over 500 million years ago. Today, we are witnessing a similar explosion in digital health solutions.
Since ONC is the certifying body for EHRs, providers must be prepared to transition to a new “Cures Edition” version of its software before the end of 2022.
MetaMe received FDA clearance for its first digital therapeutic on Tuesday. It uses behavioral therapy to help alleviate abdominal pain symptoms for patients with irritable bowel syndrome.
Odyssey Therapeutics is the latest startup formed by serial biotech entrepreneur Gary Glick. Odyssey’s destination is oncology and immunology drugs that address novel disease targets, and the biotech now has $218 million in Series A financing to fuel the journey.
Microsoft seeks to change the way pharma industry companies use technology to better navigate human resource and supply chain challenges.
A New Jersey bucked the norm of buying the off-the-shelf EHR software from the large electronic health records vendors like Epic and Cerner and built something more aligned with what was needed.
Liberating the genetics, laboratory and pharmacy data that sits deep within healthcare subsystems, while protecting patient information and navigating the global regulatory landscape, is no easy task but would greatly help in the treatment of diseases.
A study by the U.S. Department of Health and Human Services found that telehealth use increased 63-fold during the pandemic. But it also found significant disparities in telehealth use between urban and rural residents.
Nabla Bio emerged from the lab of famed Harvard scientists George Church last year, and its antibody discovery technology has already led to five partnerships with pharma and biotech companies. The startup just closed an $11 million seed financing that will support further development of its technology.
Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.
Seeking greater respect for their profession, physician assistants are pushing to rebrand themselves as “physician associates.” Meanwhile rechristening the P.A. name has spiked the blood pressures of physicians.
What do radiation and Botox have in common? Two powerful tools that were tamed by medicine in the quest to help patients. We’ve found ways to parlay our scientific curiosity and expertise into significant medical advances that help prolong and also improve quality of life.
Eli Lilly’s authorized antibody drug for treating and preventing Covid-19 infection in adolescents and adults is now authorized for pediatric patients, including newborns. While tests are still assessing whether the drug works against omicron, early data suggest a Vir Biotechnology antibody can address the new variant but Regeneron Pharmaceuticals’ antibody drug might not.
The application window is open for the startup contest Pitch Perfect at INVEST March 28-30 at the Ritz Carlton in Chicago. Here’s a look at some of the participants in the contest and progressed they’ve made on their mission to improve healthcare.
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.
There are many lessons to be learned from the Covid-19 pandemic, but perhaps the biggest is the need for proactive, long-term, and sustained investments in our public health system.
Read news from PromptHealth, HealthMine, Health2047, Sound Life Sciences, and more.
Ivermectin and other unauthorized covid treatments have become a major source of dispute in recent months. Lawsuits over hospitals’ refusals to provide ivermectin to patients have been filed in Texas, Florida, Illinois and elsewhere.
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter into this market. Omnicell is paying $100 million cash to buy ReCept.
It’s not too late for all of us to re-think health IT and bring Hippocrates’ famous quote to life: “Wherever the art of Medicine is loved, there is also a love of Humanity.”
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the progress of those drugs, UCB could earn up to $1.5 billion in milestone payments.
For researchers who aren’t affiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing and sharing them with co-workers can be even harder. A new tool by DeepDyve looks to help researchers address this gap.
Through thoughtful consumer-centric design and application, these digital fertility solutions have the potential to smooth the path towards parenthood for countless couples and individuals around the world.
In a recent webinar sponsored by 100Plus, the healthcare company provided a roadmap on how their RPM program works, including device deployment, collaboration with clinicians, implementation and reimbursement.
BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.
Sanofi’s strategy to develop new messenger RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.
The focus on glycemic management as a key indicator of patient safety was announced as part of CMS’s annual adjustment to inpatient payment policies, which are accompanied by updated rules for its Inpatient Quality Reporting (IQR) program.
Advent International, a private equity firm, is investing an undisclosed amount into Iodine boosting its valuation beyond $1 billion. The hope is that the company’s AI-powered clinical documentation improvement software can capture a greater share of the market for software products that help hospitals code and bill accurately to receive reimbursement.
Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.
The spinoff, however late, promises to make investments in GE more pure plays, which investors find easier to understand and to value. But for GE Healthcare, the real growth will be in less acute settings, and GE needs to acknowledge that trend in their strategy.
For too long, we’ve forced kids to make do with services made for adults. The results have been nothing less than tragic, as evidenced by today’s pediatric behavioral health crisis.
Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the potential to be the first or the best in their therapeutic classes.
Prescribers need a pharmacogenetics knowledge base to determine a safe and effective medication and dosage for their patients, but they also need pharmacogenetics test information to be easily accessible, interpretable and meaningful.
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress comes as the field of Treg cell therapy research becomes increasingly competitive.
More health care providers are seeing patients on an outpatient basis, but simply getting to a doctor visit can be a formidable obstacle for those managing physical and developmental disabilities.
Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track to begin human testing in non-small cell lung cancer, and Blueprint believes the small molecule has advantages over new targeted therapies from Johnson & Johnson and Takeda Pharmaceutical.
Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery. This episode of Pivot features Larry Wood, corporate vice president for TAVR with Edwards, who reflects on the journey.
California’s Senate Bill 221, which passed the state legislature with a nearly unanimous vote, requires health insurers across the state to reduce wait times for mental health care to no more than 10 business days.
When your organization asks for a lowest-net-cost formulary, what you’re really saying is, “I want the deepest contractual discounts aligned with my formulary without disruption.”
While overall spending may not yet correspond to the totality of the cybersecurity threat landscape, asset management has emerged as a primary area of opportunity for hospitals and healthcare systems to invest in as they ‘up’ their cybersecurity game and put greater emphasis on risk reduction.
The new Covid-19 variant, named Omicron, has mutations that could help it evade antibodies produced by the immune system. Scientists are conducting lab tests to better understand this new variant and pharmaceutical companies are testing how existing vaccines, as well as those in development, measure up the new mutations.
The Toronto-based startup is applying AI to ultrasound signals. It differentiates healthy tissue from diseased tissue by measuring its acoustic properties.
Working on unthinkably large datasets and integrating them with massive amounts of computing power, unleashing millions of trained machine-learning models to inform clinical decision making in real time that factor in all of these elements that make up a person — this will enable significantly better clinical outcomes.
In the future – virtual care 2.0 – must build upon this understanding and focus on a new KPI (key performance indicator): patient autonomy, the ability of a person to treat themselves effectively and feel confident in their decisions.
Novel health technologies are allowing us to move into a new era of equality and improved access to healthcare for everyone, eliminating the barriers between people and healthcare, by putting the patient at the center of care versus the provider.
The pandemic changed ideas and helped create new solutions to improve how and where patients access care whether it be through a smartphone-based transportation app with healthy meal delivery or remote patient monitoring.
A federal jury found pharmacy chains CVS, Walgreens and Walmart helped fuel the opioid epidemic in two Ohio counties. It’s the first trial pharmacy chains have faced related to the opioid crisis, though several other lawsuits have been filed.
The FDA placed a partial clinical hold on a Kura Oncology leukemia drug following the death of one patient in the early-stage study. Kura executives said the death may be related to differentiation syndrome, a known complication of leukemia therapies.
Spurred by Covid-19, we are witnessing the unprecedented digital transformation of healthcare, and health systems […]
Takeda Pharmaceutical won FDA approval for Livtencity, an antiviral developed to treat cytomegalovirus infection in transplant patients. The agency also approved an Aadi Biosciences drug, making it the first therapy authorized for treating a rare type of soft-tissue cancer.